EL7.AI
Mergers & AcquisitionsMedium•3 August 2026•
2 min read

Supernus and Indivior to Merge in All-Stock CNS Biopharma Deal

Key Facts

1Supernus and Indivior announced a definitive agreement to combine in a tax-free all-stock merger of equals.
2The transaction is expected to realize $125 million in annual cost synergies.
3The combined entity will be named Supernus, Inc. and will list on Nasdaq under the ticker SUPN.

In a move reflecting the accelerating consolidation within the biotechnology sector, Supernus and Indivior have announced a definitive merger agreement to create a leader in the central nervous system (CNS) market. The transaction is structured as a tax-free all-stock merger of equals, where Indivior stockholders will own approximately 56.5% and Supernus stockholders will own 43.5% of the combined company. The new entity will operate under the name Supernus, Inc. and is set to list on the Nasdaq exchange under the ticker SUPN.

This strategic combination is expected to realize significant annual cost synergies of $125 million, strengthening the financial position of the combined entity in the CNS biopharma space. According to reports, Jack Khattar will serve as CEO of the combined company, while Tony Kingsley will take the role of Board Chair. The announcement follows strong financial performance from Supernus, which reported second-quarter 2026 revenues of $219.1 million, marking a 32% increase compared to the same period last year.

On the broader economic front, U.S. Goods Trade Balance data from July 28, 2026, showed a deficit of $101.5 billion, which was narrower than previous figures, providing a mixed backdrop for the pharmaceutical manufacturing sector. Investors will also monitor the outcomes of recent OPEC meetings for indirect impacts on industrial operating costs.